On the path to 2025: Understanding the Alzheimer's disease continuum

Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens, Bruno Dubois

Research output: Contribution to journalReview article

75 Scopus citations

Abstract

Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer's disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease and the spectrum of AD spans from clinically asymptomatic to severely impaired. Defining AD purely by its clinical presentation is thus artificial and efforts have been made to recognize the disease based on both clinical and biomarker findings. Advances with biomarkers have also prompted a shift in how the disease is considered as a clinico-pathophysiological entity, with an increasing appreciation that AD should not only be viewed with discrete and defined clinical stages, but as a multifaceted process moving along a seamless continuum. Acknowledging this concept is critical to understanding the development process for disease-modifying therapies, and for initiating effective diagnostic and disease management options. In this article, we discuss the concept of a disease continuum from pathophysiological, biomarker, and clinical perspectives, and highlight the importance of considering AD as a continuum rather than discrete stages. While the pathophysiology of AD has still not been elucidated completely, there is ample evidence to support researchers and clinicians embracing the view of a disease continuum in their study, diagnosis, and management of the disease.

Original languageEnglish (US)
Article number60
JournalAlzheimer's Research and Therapy
Volume9
Issue number1
DOIs
StatePublished - Aug 9 2017

Keywords

  • Alzheimer's disease
  • Amyloid beta
  • Biomarker
  • Clinical
  • Cognitive impairment
  • Continuum
  • Dementia
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Fingerprint Dive into the research topics of 'On the path to 2025: Understanding the Alzheimer's disease continuum'. Together they form a unique fingerprint.

  • Cite this

    Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., Scheltens, P., & Dubois, B. (2017). On the path to 2025: Understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 9(1), [60]. https://doi.org/10.1186/s13195-017-0283-5